- Open Access
- Open Peer Review
Influence of E-smoking liquids on human periodontal ligament fibroblasts
© Willershausen et al.; licensee BioMed Central Ltd. 2014
- Received: 13 May 2014
- Accepted: 11 September 2014
- Published: 15 September 2014
Over the last years, electronic cigarettes (ECs) have become more popular, particularly in individuals who want to give up smoking tobacco. The aim of the present study was to assess the influence of the different e-smoking liquids on the viability and proliferation of human periodontal ligament fibroblasts.
Method and materials
For this study six test solutions with components from ECs were selected: lime-, hazelnut- and menthol-flavored liquids, nicotine, propylene glycol, and PBS as control group. The fibroblasts were incubated up to 96 h with the different liquids, and cell viability was measured by using the PrestoBlue® reagent, the ATP detection and the migration assay. Fluorescence staining was carried out to visualize cell growth and morphology. Data were statistically analyzed by two-tailed one-way ANOVA.
The cell viability assay showed that the proliferation rates of the cells incubated with nicotine or the various flavored liquids of the e-cigarettes were reduced in comparison to the controls, though not all reductions were statistically significant. After an incubation of 96 h with the menthol-flavored liquid the fibroblasts were statistically significant reduced (p < 0.001). Similar results were found for the detection of ATP in fibroblasts; the incubation with menthol-flavored liquids (p < 0.001) led to a statistically significant reduction. The cell visualization tests confirmed these findings.
Within its limits, the present in vitro study demonstrated that menthol additives of e-smoking have a harmful effect on human periodontal ligament fibroblasts. This might indicate that menthol additives should be avoided for e-cigarettes.
- Cell proliferation
- Electronic cigarettes
- In vitro
The electronic nicotine-delivery device (electronic cigarettes, ECs) was developed and patented in 2003 by the Ruyan Group (Holdings) Limited in Beijing, China. After their launch on the market in Europe and the United States of America in 2006, e-cigarettes made headlines across the world . Praised as an alternative to conventional cigarettes, e-cigarettes are intended for those who want to reduce or quit smoking. They can be used indoors when restrictions on conventional smoking are present, and have been marketed as environmentally friendly. The e-cigarette is an electronic nicotine delivery device that mimics the outward appearance of a conventional cigarette and has been recently introduced to the market worldwide . While many different models are commercially available, all e-cigarettes consist of little more than three basic components: a battery-part, a heating element and a liquid-containing cartridge. The cartridge can be filled with different e-liquid solutions. These liquids are vaporized by the heating element, and the cigarette is ‘consumed’ by inhaling the liquids’ aerosol mist, thus simulating the act of real tobacco smoking. The e-liquid is a simple solution with usually three main components. They contain diluents added to dilute the mixture and to vaporize upon heating; the most commonly used diluents are propylene glycol and vegetable or aqueous glycerin, usually as a mixture of 80% propylene glycol and 20% glycerin. In addition, flavors are often added to improve the taste of the e-liquid. Nicotine is often added to the propylene glycol in concentrations up to 70 mg/ml. Propylene glycol, a colorless and odorless food additive, is a safe, commonly used chemical without any known harmful effects on human health. Nicotine, in contrast, is considered very harmful to both general and dental health. Tobacco smoke induces changes in cell structure and function by altering cell signaling pathways, which is predominantly harmful to bronchial and oral epithelial cells [3–5]. Adverse consequences on human health have been shown even for low cigarette consumption . Cigarette smoke contains approximately 4800 chemicals, over 60 of which are known to have adverse effects on human tissues and cells, e.g. a high genotoxicity leading to various forms of DNA damage . Tobacco smoking is responsible for 85% of lung carcinomas. According to WHO reports, cancer of the oral cavity is the eleventh most common cancer worldwide , while in South Central Asia it is the forth most common cancer . Besides being harmful to overall health, the connection between smoking tobacco and developing periodontal disease is well documented in the literature. Studies have shown that smoking tobacco contributes to the progression of periodontal disease and adversely affects patients’ response to non-surgical or surgical treatment [10–16]. Higher failure rates and increased complications after dental implant placement have also been documented in smokers . Likewise, smoking is a predisposing factor to acute necrotizing ulcerative gingivitis . Exposure to cigarette smoke is also considered an independent periodontal disease risk factor. Although e-cigarettes were initially introduced as a healthy alternative to conventional smoking; however, when they contain e-liquids supplemented with nicotine, health risks associated with conventional tobacco consumption might be expected. In a recent study it was shown that 10 to 81% of the nicotine from the cartridges was vaporized, corresponding to a range of 2.1 to 15.1 mg nicotine . According to a survey among users, e-cigarettes are very popular, because they are supposed to assist with smoking cessation . In in-vitro studies it has been shown that the vapors of the electronic cigarettes were significantly less cytotoxic than cigarette smoke extract .
The manufacturing process for e-liquids is not yet standardized, which carries the risk that cancer-inducing substances will enter the wide variety of e-liquids available on the market [22–25]. To date, tobacco-specific substances such as nitrosamines and aldehydes have already been detected in e-liquids. Since no evidence-based studies on the effectiveness of e-cigarettes for smoking cessation presently exist, and since the potentially harmful health effects of e-cigarettes have also not been tested, the use of e-cigarettes to replace cigarette smoking can not be recommended.
The aim of the present in vitro study was to examine, whether e-cigarette liquids and their various flavor components have a damaging influence on the viability and proliferation of human periodontal ligament fibroblast.
Clonetics® HPdLF (Human Periodontal Ligament Fibroblasts) were purchased from Lonza (BioWhittaker, Kerviers, Belgium). The fibroblasts were cultured in Dulbecco’s Modified Eagle Medium (Molecular Probes, Carlsbad, CA) containing 1% penicillin/streptomycin (Molecular Probes, Carlsbad, CA) and 10% fetal bovine serum (PAA, Pasching, Austria) and incubated under standard cultivation conditions (37°C, 5% CO2 and 95% air). Cells from the 4th to the 6th passage were used for the PrestoBlue Viability Assay, the ApoGlow BioAssay, cell visualization by means of fluorescence staining and the Migration Assay.
Liquids for electronic cigarettes
The tested e-smoking liquids (eSmokerShop, GmbH, Hannover, Germany) all contained in addition to various flavors the components nicotine (20–22 mg/ml) and, as additive, propylene glycol. Liquids with the flavors hazelnut (filbertone; trans-5-Methyl-2-hepten-4-one; 20 mg/ml nicotine) , lime (20 mg/ml nicotine) [27, 28] and menthol (5-methyl-2-propan-2-ylcyclohexan-1-ol; 22 mg/ml nicotine) as well as the test substances nicotine and propylene glycol (Sigma-Aldrich Chemie GmbH, Steinsheim, Germany) were included in the investigation. Dose–response curves were established for nicotine and for the menthol-flavored e-smoking liquid. From preliminary experiments with the menthol-flavored liquid a concentration of 10 μg/ml was determined as best suited for all tests described below. To allow for comparisons, all test liquids were therefore diluted with serum-free Dulbecco’s Modified Eagle Medium (DMEM), resulting in a final nicotine concentration of 10 μg nicotine per ml test liquid. There were in total six test groups: control group (PBS); propylene glycol; nicotine; three e-liquids, one with hazelnut flavor, one with lime flavor and one with menthol flavor. The following assays were employed to study the influence of the above mentioned test solutions on the vitality and proliferation of fibroblast cells.
PrestoBlue Cell Viability Assay
The PrestoBlue Cell proliferation assay (Molecular Probes, Carlsbad, CA) contains a growth indicator which becomes reduced by metabolically active cells to a fluorescent agent. To investigate the influence of the different liquids, the periodontal fibroblasts (10,000 cells/200 μl; n = 6 for each test) were placed into 96 multi well plates and were then incubated up to 96 h with the different liquids. Control cells were incubated only with the same volume of DMEM.
After 0,1,3,6, 24, 72 and 96 h of incubation with 5% PrestoBlue, fluorescence was measured at a wavelength of 530/25 nm and 590/35 nm with a fluorescence reader (Synergy HT-Reader, BioTek, Winooski, VT). Logarithmic signals were converted to a linear scale and expressed as relative fluorescence units (RFU).
The ATP detection was performed with the ApoGlow Bioassay kit (Lonza, BioWhittaker, Kerviers, Belgium). For this assay 30,000 cells/well (n = 6 for each test) were grown to confluence for about 24 h. The supernatants were removed and the cells were incubated for 24 h with the various test liquids. Then ATP was determined using the ApoGlow Bioassay kit. Luminescence was measured with a luminescence reader (Synergy HT-Reader, BioTek, Winooski, VT) and analyzed with Gen 5 (BioTek, Winooski, VT).
Calcein-AM/ethidium homodimer II staining (LIVE/DEAD Viability/Cytotoxicity Kit; Molecular Probes, Carlsbad, CA) is a two-color fluorescence-based method for determining viability of cultured cells. Calcein is a fluorogenic esterase substrate that is hydrolyzed intracellularly to a green fluorescent product, which is an indicator of live cells. Ethidium homodimer enters cells with damaged membranes and intercalates with the DNA in the nucleus, emitting a red fluorescent signal. For cell visualization, the fibroblasts were incubated for 24 h with the different test solutions and after removal of the supernatant incubated with calcein-AM (5 μl/10 ml)/ethidium homodimer II (10 μl/10 ml) at 37°C for 15 min. The stained cells were then viewed in an inverted microscope at wave lengths of 450/520 nm (Axiovert 40C, Carl Zeiss, Jena, Germany) at a magnification of ×100.
The migration assay (Greiner Bio-One GmbH, Frickenhausen, Germany) was performed with Boyden-Chambers (ThinCerts, Greiner Bio-One GmbH, Frickenhausen, Germany). For this investigation the fibroblasts (10,000 cells/well; n = 6 for each test) were placed in Boyden-Chambers. The two compartments of the Boyden-Chamber are separated by a porous PET membrane. Then the test liquids (600 μl with a final concentration of 10 μg/ml nicotine) were added and incubated for 72 h at standard culture conditions. Migratory cells move through the pores. The fibroblasts were stained with calcein-AM (5 μl and 10 ml PBS) for 15 min under culture condition. After incubation the cells were rinsed, placed in a new 24 multi-well chamber, and then incubated for 30 min with 300 μl trypsin/EDTA. Afterwards, aliquots of 200 μl were placed in a black 96 multi-well plate. Fluorescence was measured at a wavelength of 485/20 nm and 520/40 nm with a fluorescence reader (Synergy HT-Reader, BioTek, Winooski, VT) and analyzed with Gen 5 (BioTek, Winooski, VT). Logarithmic signals were converted to a linear scale and expressed as relative fluorescence units (RFU).
The statistical analyses of the data were performed using SPSS 20.0 (SPSS Inc., Chicago, Il.). For descriptive analyses, means and standard deviations were calculated for the normally distributed continuous outcome variables.
For confirmatory analyses two-tailed one-way ANOVA were performed to calculate overall p-values for the comparison of the different groups for each outcome variable.
Normality for outcomes was checked by visual inspection via quantile-quantile plots.
A power analysis for an ANOVA design was performed. With a sample size of n = 6 per group a power between 75% and 100% is available for 7 outcomes.
The global significance level for all statistical test procedures was chosen as α = 0.05.
Post-hoc tests employing the Bonferroni correction for multiple testing were used for comparison of means of two groups.
In the present study a possible harmful influence of components and different available flavors of e-cigarettes on human fibroblast cells was examined. E-cigarettes have received a great deal of attention and popularity over the past years and they also play an important role in nicotine replacement therapy . E-cigarettes present a valuable alternative for smokers who are willing to quit. Therefore, it is of interest to what extent the main components of the electronic cigarette smoking liquids are potentially harmful. A novelty in e- cigarettes is flavoring as additive and the liquids come in great variety .
In our in vitro study it was demonstrated that some additives from e-cigarettes could cause considerable damage to cell proliferation. While some flavorings such as lime or hazelnut did not seem to exert a harmful effect on cell vitality and proliferation, the menthol e-liquid preparation had significant negative impact on periodontal ligament fibroblasts.
In their in vitro study Semlali et al.  explored the influence of whole cigarette smoke on the morphology and function of gingival fiboblasts. The authors were able to prove reduced cellular proliferation and vitality, further a reduction of the number of β1-integrin-positive cells together with an increased LDH activity . These results demonstrate that even a single exposure to cigarette smoke can produce morphological and functional deregulation in gingival fibroblasts.
The effect of numerous refill solutions of e-cigarettes from an American distributor on human embryonic stem cells and human pulmonary fibroblasts were tested, and it was also shown that various additives such as cinnamon or menthol had a cytotoxic potential .
It is known that in particular menthol as a tobacco additive has the effect of masking the bitter taste of cigarette smoke; it was first introduced into cigarettes in 1926 .
Conventional and electronic cigarettes often contain menthol. Various effects have been suggested for menthol, such as taste ameliorating, cooling, pain-relieving and a slightly numbing effect; menthol ameliorates the cigarette taste, masks the irritating effect of tobacco smoke and makes the smoke easier to inhale . Furthermore, the potential for addiction is increased through its desensitization ability to nicotine, longer exposure and tolerance to nicotine. Finally the risk of cancer is increased by absorption of tobacco smoke components into the lung [33–36]. Menthol can be contained in several parts of cigarettes, such as in the filter, paper and also in flavored liquids.
Recent studies confirm that the addition of menthol leads to a number of negative effects [37, 38]. Furthermore, it was shown that menthol increases the flux of the tobacco-related compounds nitrosamine and nitrosonornicotine across porcine esophagus . It is remarkable that one third of diagnosed esophageal cancers in 1998 was found in females  and that about a third of female smokers preferred menthol cigarettes .
The harmful effect of additives, in particular with menthol flavor could also be observed and confirmed in our study.
Results from numerous studies providing evidence of a negative influence of menthol additives in cigarettes have lead in 2013 to the decision to ban menthol containing cigarettes in the European Community; in addition, it was proposed to harmonize the regulations of e-cigarettes, which presently differ between the countries in the EU, and to restrict their advertising . Since the present study shows that in particular menthol additives in e-cigarettes had a harmful effect on human fibroblast cells, it might be considered to prohibit the use of this additive not only in conventional cigarettes but also in e-cigarettes.
Within its limits, the present in vitro study demonstrated that menthol additives of e-smoking have a harmful effect on human periodontal ligament fibroblasts. This might indicate that it is preferable for e-cigarettes not to contain menthol additives.
The authors would like to thank Mrs. Claudia Darmstadt for her excellent technical assistance.
- Yamin CK, Bitton A, Bates DW: E-Cigarettes: a rapidly growing internet phenomenon. Ann Intern Med. 2010, 153 (9): 607-609. 10.7326/0003-4819-153-9-201011020-00011.View ArticlePubMedGoogle Scholar
- Henningfield JE, Zaatari GS: Electronic nicotine delivery systems: emerging science foundation for policy. Tob Control. 2010, 19 (2): 89-90. 10.1136/tc.2009.035279.View ArticlePubMedGoogle Scholar
- Carter CA, Hamm JT: Multiplexed quantitative high content screening reveals that cigarette smoke condensate induces changes in cell structure and function through alterations in cell signaling pathways in human bronchial cells. Toxicology. 2009, 261 (3): 89-102. 10.1016/j.tox.2009.04.039.View ArticlePubMedGoogle Scholar
- Chen YT, Gallup M, Nikulina K, Lazarev S, Zlock L, Finkbeiner W, McNamara N: Cigarette smoke induces epidermal growth factor receptor-dependent redistribution of apical MUC1 and junctional beta-catenin in polarized human airway epithelial cells. Am J Pathol. 2010, 177 (3): 1255-1264. 10.2353/ajpath.2010.091129.View ArticlePubMedPubMed CentralGoogle Scholar
- Donetti E, Gualerzi A, Bedoni M, Volpari T, Sciarabba M, Tartaglia G, Sforza C: Desmoglein 3 and keratin 10 expressions are reduced by chronic exposure to cigarette smoke in human keratinised oral mucosa explants. Arch Oral Biol. 2010, 55 (10): 815-823. 10.1016/j.archoralbio.2010.07.001.View ArticlePubMedGoogle Scholar
- Bjartveit K, Tverdak A: Health consequences of smoking 1–4 cigarettes per day. Tob Control. 2005, 14 (5): 315-320. 10.1136/tc.2005.011932.View ArticlePubMedPubMed CentralGoogle Scholar
- Mills AL, Messer K, Gilpin EA, Pierce JP: The effect of smoke-free homes on adult smoking behavior: a review. Nicotine Tob Res. 2009, 11 (10): 1131-1141. 10.1093/ntr/ntp122.View ArticlePubMedGoogle Scholar
- Stewart BW, Kleihues P: World Cancer Report. Lyon: WHO International Agency for Research on Cancer. 2003, 1-351.Google Scholar
- Boyle P, Levin B: World Cancer Report. Lyon: WHO International Agency for Research on Cancer. 2008, 1-511.Google Scholar
- Johnson GK, Guthmiller JM: The impact of cigarette smoking on periodontal disease and treatment. Periodontol 2000. 2007, 44: 178-194. 10.1111/j.1600-0757.2007.00212.x.View ArticlePubMedGoogle Scholar
- Kibayashi M, Tanaka M, Nishida N, Kuboniwa M, Kataoka K, Nagata H, Nakayama K, Morimoto K, Shizukuishi S: Longitudinal study of the association between smoking as a periodontitis risk and salivary biomarkers related to periodontitis. J Periodontol. 2007, 78 (5): 859-867. 10.1902/jop.2007.060292.View ArticlePubMedGoogle Scholar
- Silva D, Cáceres M, Arancibia R, Martínez C, Martínez J, Smith PC: Effects of cigarette smoke and nicotine on cell viability, migration and myofibroblastic differentiation. J Periodont Res. 2012, 47 (5): 599-607. 10.1111/j.1600-0765.2012.01472.x.View ArticlePubMedGoogle Scholar
- Calsina G, Ramon JM, Echeverria JJ: Effects of smoking on periodontal tissues. J Clin Periodontol. 2002, 29 (8): 771-776.View ArticlePubMedGoogle Scholar
- Wan CP, Leung WK, Wong MC, Wong RM, Wan P, Lo EC, Corbet EF: Effects of smoking on healing response to non-surgical periodontal therapy: a multilevel modelling analysis. J Clin Periodontol. 2009, 36 (3): 229-239. 10.1111/j.1600-051X.2008.01371.x.View ArticlePubMedGoogle Scholar
- Moimaz SA, Zina LG, Saliba O, Garbin CA: Smoking and periodontal disease: clinical evidence for an association. Oral Health Prev Dent. 2009, 7 (4): 369-376.PubMedGoogle Scholar
- Torrungruang K, Gongsakdi V, Laohaviraphab L, Likittanasombat K, Ratanachaiwong W: Association between cigarette smoking and the intraoral distribution of periodontal disease in Thai men over 50 years of age. J Investig Clin Dent. 2012, 3 (2): 135-141. 10.1111/j.2041-1626.2011.00105.x.View ArticlePubMedGoogle Scholar
- Chen H, Liu N, Xu X, Qu X, Lu E: Smoking, radiotherapy, diabetes and osteoporosis as risk factors for dental implant failure: a meta-analysis. PLoS One. 2013, 8 (8): e71955-10.1371/journal.pone.0071955. doi10.1371/journal.phone.0071955View ArticlePubMedPubMed CentralGoogle Scholar
- Underner M, Perriot J, Peiffer G: Le snus. Presse Med. 2012, 41 (1): 3-9. 10.1016/j.lpm.2011.06.005.View ArticlePubMedGoogle Scholar
- Goniewicz ML, Hajek P, McRobbie H: Nicotine content of electronic cigarettes, its release in vapour and its consistency across batches: regulatory implications. Addiction. 2014, 109 (3): 500-507. 10.1111/add.12410.View ArticlePubMedGoogle Scholar
- Etter JF: Electronic cigarettes. A survey of users. BMC Public Health. 2010, 10 (4): 231-View ArticlePubMedPubMed CentralGoogle Scholar
- Romagna G, Allifranchini E, Bocchietto E, Todeschi S, Esposito M, Farsalinos KE: Cytotoxicity evaluation of electronic cigarette vapor extract on cultured mammalian fibroblasts (ClearStream-Life): comparison with tobacco cigarette smoke extract. Inhal Toxicol. 2013, 25 (6): 354-461. 10.3109/08958378.2013.793439.View ArticlePubMedGoogle Scholar
- Kim HJ, Shin HS: Determination of tobacco-specific nitrosamines in replacement liquids of electronic cigarettes by liquid chromatography–tandem mass spectrometry. J Chromatogr A. 2013, 1291 (24): 48-55.View ArticlePubMedGoogle Scholar
- Goniewicz ML, Kuma T, Gawron M, Knysak J, Kosmider L: Nicotine levels in electronic cigarettes. Nicotine Tob Res. 2012, 15 (1): 158-166.View ArticlePubMedGoogle Scholar
- Chen IL: FDA summary of adverse events on electronic cigarettes. Nicotine Tob Res. 2013, 15 (2): 615-616. 10.1093/ntr/nts145.View ArticlePubMedGoogle Scholar
- Etter JF, Zäther E, Svensson S: Analysis of refill liquids for electronic cigarettes. Addiction. 2013, 108 (9): 1671-1679. 10.1111/add.12235.View ArticlePubMedGoogle Scholar
- Jauch J, Schmalzing D, Schurig V, Emberger R, Hopp R, Köpsel M, Silberzahn W, Werkhoff P: Isolation, synthesis, and absolute configuration of filbertone-the principal flavor component of the hazelnut. Angew Chem Int Ed Engl. 1989, 28: 1022-1023. 10.1002/anie.198910221.View ArticleGoogle Scholar
- Clark BC, Chamblee TS, Iacobucci GA: HPLC isolation of the sesquiterpene hydrocarbon germacrene B from lime peel oil and its characterization as an important flavor impact constituent. J Agric Food Chem. 1987, 35: 514-518. 10.1021/jf00076a019.View ArticleGoogle Scholar
- Loizzo MR, Tundis R, Bonesi M, Menichini F, De Luca D, Colica C, Menichini F: Evaluation of Citrus aurantifolia peel and leaves extracts for their chemical composition, antioxidant and anti-cholinesterase activities. J Sci Food Agric. 2012, 92: 2960-2967. 10.1002/jsfa.5708.View ArticlePubMedGoogle Scholar
- Ayers JW, Ribisl KM, Brownstein JS: Tracking the rise in popularity of electronic nicotine delivery systems (electronic cigarettes) using search query surveillance. Am J Prev Med. 2011, 40 (4): 448-453. 10.1016/j.amepre.2010.12.007.View ArticlePubMedGoogle Scholar
- Semlali A, Chakir J, Rouabhia M: Effects of whole cigarette smoke on human gingival fibroblast adhesion, growth, and migration. J Toxicol Environ Health A. 2011, 74 (13): 848-862. 10.1080/15287394.2011.570230.View ArticlePubMedGoogle Scholar
- Bahl V, Lin S, Xu N, Davis B, Wang Y: Comparison of electronic cigarette refill fluid cytotoxicity using embryonic and adult models. Reprod Toxicol. 2012, 34 (4): 529-537. 10.1016/j.reprotox.2012.08.001.View ArticlePubMedGoogle Scholar
- Squier CA, Mantz MJ, Wertz PW: Effect of menthol on the penetration of tobacco carcinogens and nicotine across porcine oral mucosa ex vivo. Nicotine Tob Res. 2010, 12 (7): 763-7. 10.1093/ntr/ntq084.View ArticlePubMedGoogle Scholar
- Ahijevych K, Garrett BE: Menthol pharmacology and its potential impact on cigarette smoking behavior. Nicotine Tob Res. 2004, 6 (1 Suppl): S17-S28.View ArticlePubMedGoogle Scholar
- Dessirier JM, O‘Mahony M, Carstens E: Oral irritant properties of menthol: sensitizing and desensitizing effects of repeated application and cross-desensitization to nicotine. Physiol Behav. 2001, 73 (1–2): 25-36.View ArticlePubMedGoogle Scholar
- Garten S, Falkner RV: Role of mentholated cigarettes in increased nicotine dependence and greater risk of tobacco-attributable disease. Prev Med. 2004, 38 (6): 793-798. 10.1016/j.ypmed.2004.01.019.View ArticlePubMedGoogle Scholar
- Kreslake JM, Wayne GF, Connolly GN: The menthol smoker: tobacco industry research on consumer sensory perception of menthol cigarettes and its role in smoking behavior. Nicotine Tob Res. 2008, 10 (4): 705-715. 10.1080/14622200801979134.View ArticlePubMedGoogle Scholar
- Lu HF, Liu JY, Hsueh SC, Yang YY, Yang JS, Tan TW, Kok LF, Lu CC, Lan SH, Wu SY, Liao SS, Ip SW, Chung JG: Menthol inhibits WEHI-3 leukemia cells in vitro and in vivo. In Vivo. 2007, 21 (2): 285-289.PubMedGoogle Scholar
- Squier CA, Mantz MJ, Wertz PW: Effect of menthol on the penetration of tobacco carcinogens and nicotine across porcine oral mucosa ex vivo. Nicotine Tob Res. 2010, 12 (7): 763-767. 10.1093/ntr/ntq084.View ArticlePubMedGoogle Scholar
- Azzi C, Zhang J, Purdon CH, Chapman JM, Nitcheva D, Hebert JR, Smith EW: Permeation and reservoir formation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and benzo [a]pyrene (B [a]P) across porcine esophageal tissue in the presence of ethanol and menthol. Carcinogenesis. 2006, 27 (1): 137-145.View ArticlePubMedGoogle Scholar
- Brooks-Brunn JA: Esophageal cancer: an overview. Medsurg Nurs. 2000, 95 (9): 248-254.Google Scholar
- Giovino GA, Sidney S, Gfroerer JC, O‘Malley PM, Allen JA, Richter PA, Cummings KM: Epidemiology of menthol cigarette use. Nicotine Tob Res. 2004, 6 (1 Suppl): S67-S81.View ArticlePubMedGoogle Scholar
- European Union: Proposal for a directive of the European Parliament and of the Council on the approximation of the laws, regulations and administrative provisions of the member states concerning the manufacture, presentation and sale of tobacco and related products. 2012,http://www.ec.europa.eu/health/tobacco/docs/com_2012_788_en.pdf,Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.